PubMed Health⌕ Search

Biomedical subjects

T V Dolgopolova

Publications and source records attributed to T V Dolgopolova.

12 recordsLinked to original sources
PubMedDate not supplied

[Preventive analgesia: a new trend in anesthesiology. An idea born and developed at the P.A. Herzen Institute of Oncology].

The authors summarize positive experience gained in the use of preventive anesthesia in oncosurgery. The new trend in anesthesiology has been developed at P. A. Herzen Institute of Oncology since the end of the eighties. A peripheral analgesic (aspisol, ketoprofene, ketorolac, etc.) was added to traditional premedication and anesthesia protocols in 522 patients subjected to extensive cavitary and other than cavitary surgery. Hemodynamic and metabolic parameters, homeostasis, stress criteria (hydrocortisone and glucose), pain intensity according to the verbal evaluation scale were studied at all stages of anesthesia and postoperative period, and side effects of postoperative analgesia were analyzed. Use of nonsteroid antiinflammatory drugs before the intervention and in the postoperative period prevented the development of strong postoperative pain and notably decreased the need in opioid analgesics in the presence of stable homeostasis. No serious side effects of analgesics, including hemorrhagic complications, were observed.

Adult↗
PubMedDate not supplied

[Ketoprofen (ketonal): a drug for preventing and treating postoperative pain].

A prophylactic approach to the management of postoperative pain is described: ketoprofen, a nonsteroid antiinflammatory drug, was used, which possesses numerous advantages and a variety of dosage forms. To cancer patients subjected to extensive radical operations on the pelvic organs, head, and neck, ketonal (ketoprofen) was injected intramuscularly or rectally in a dose of 100 mg 1 h before surgery and in a daily dose of 300 mg during the postoperative period. Adequate postoperative monoanalgesia with ketonal was attained in 47% patients. In the rest patients ketonal was combined with medium-potent opioid tramadol. A more potent opioid buprenorfin (sangesik) in the minimal daily dose of 0.3 mg was required in only 2 cases. Nonsteroid antiinflammatory drug ketoprofen (ketonal) in therapeutic doses administered preventively before surgery intramuscularly or rectally notably decreased the acuity of the postoperative pain syndrome.

Administration, Rectal↗
PubMedDate not supplied

[Use of analgesics with peripheral action in the system of complex protection of the patient from operative trauma].

Obtained for many years experience of perioperative using of analgesics with peripheral effect is summarized. The special scientific analysis was carried out in 274 patients who got different analgesics with peripheral action (aspisol, baralgin, ketoprofen, ketorolak, contrikal) at different stages of preoperative period in combination with opioid. The control group included 30 patients who got monoanalgesia by promedol after abdominal operations. The dynamics of pain, hemodynamics, respiration, gas-exchange, blood coagulation and rheology indices as well as side effects of analgesics were estimated. The best results have been obtained in cases with preventive therapy by non-steroid anti-inflammatory drug 1 hour before beginning of operation and subsequent therapy continuation after operation. Under such conditions complete analgesia after operation with moderate traumaticity is achieved in combination with low dose of small opioid (tramal) in daily dose of 235 mg. The introducing of non-steroid anti-inflammatory drugs was not followed by any hemorrhagic complication, and as was evident from electrocoalugraphic data improved blood rheology. After severe traumatic abdominal or thoracal operations non-steroid anti-inflammatory drugs are used in combination with other potent analgesic with peripheral action--cortical and opioid buprenofine in minimal dose of 0.35 mg/day with good analgesic effect. To prevent the central sensitization during general anesthesia ketamine in microdose 0.5-1.0 mg/kg*hour is always used. The conclusion is made on the important role of multimodal preventive and continuous perioperative antinociceptive protection.

Analgesia↗
PubMedDate not supplied

[Norfin in oncological practice].

A synthetic opiate agonist-antagonist norphin (buprenorphin) has been studied in 297 cancer patients as an analgetic component of general anesthesia, in postoperative analgesia and in the treatment of chronic pain syndrome. In modified neuroleptanalgesia based on norphin, diazepam, droperidol and N2O the patient is more adequately prevented from surgical trauma than in conventional neuroleptanalgesia based on fentanyl. This is confirmed by greater stability in circulation, metabolism and stress hormone parameters, however this anesthesia technique is less manageable and may be accompanied by prolonged postanesthesia depression of the central nervous system. Good results have been obtained when norphin pills were used sublingually for the treatment of long-lasting intensive chronic pain syndrome in incurable cancer patients. Norphin is no less effective than morphin, however, unlike morphin, it causes no severe adverse reactions.

Adult↗
PubMedDate not supplied

[Lornoxicam (xefocam) as an agent for the prevention and treatment of postoperative pain among other nonsteroidal anti-inflammatory drugs].

Lornoxicam (xefocam) as an agent of perioperative antinociceptive defense was studied and compared with other nonsteroidal anti-inflammatory drugs (NSAIDs) (ketorolac, ketoprofen). A comparative study was performed in 140 cancer surgical patients who were mainly middle-aged and elderly (51 +/- 10.9 years) and who had various concomitant diseases (ASA II-III). Extensive oncological operations under multicomponent general anesthesia were performed in these patients on the abdomen (n=60), small pelvis (n=46), and head and neck (n=34). All NSAIDs were used on the principle of preemptive analgesia, by intramuscularly injecting the therapeutic dose of an analgesic 40-60 min before surgery and by further continuing this basic therapy in combination with an opioid after surgery. Thirty patients received lornoxicam (xefocam, 16 mg/day), 30 had ketorolac (ketanov, 60-90 mg/day), 30, ketoprofen/ketonal (200 mg/day), and 20 patients, ketoprofen/artrozilene (320 mg/day). A control group comprised 30 patients who did not receive NSAIDs. In the patients of all the groups, the anesthesia scheme included one more antinociceptive agent--the kininogenesis inhibitor contrical (the total dose was 50,000-60,000 ATrU) (beginning from the stage of induction) and its administration (30,000 ATrU/day) was continued within 2 days after surgery. The studies performed have established that lornoxicam (xefocam) used in therapeutic doses shows a 50% reduction (versus 30% when ketorolac or ketoprofen is used) in a need for the potent opioid bepronorfine after extensive operations for cancer is one of the most effective NSAIDs. It has been noted that a short-term course of perioperative therapy with NDAIDs does not cause complications or side effects if individual contraindications to and limitations on their use are followed.

Adult↗
PubMedDate not supplied

[The new Soviet narcotic analgesic phenaridine as a component of general anesthesia during cancer surgery].

The results of studies on 65 cancer patients operated on under modified neuroleptanalgesia using fenaridine give evidence of a more potent and prolonged analgetic effect of a new Soviet narcotic analgesic fenaridine as compared to fentanyl. Fenaridine ensures stable neuroautonomous protection of the body during cancer surgery and is indicated in prolonged traumatic surgical interventions with cardiopulmonary bypass. Along with the above advantages fenaridine possesses all the complex of side effects typical of opiates associated with the depression of respiratory centres, psychoemotional sphere, activation of parasympathetic centres which may complicate the period following the patient's withdrawal from anesthesia and necessitate prolonged controlled lung ventilation in the early postoperative period. Thus, during 3-5-hour-long surgery it is advisable to administer the basic amount of the overall drug dose during the first 1-1.5 h of anesthesia and surgery, which promotes the awakening of most patients 10-15 min after surgery. Another drawback of fenaridine is the onset of marked rigor and signs of microcirculation disturbances upon discontinuation of the drug effect.

4-Aminopyridine↗
PubMedDate not supplied

[Klofelin as a component of general anesthesia and a means of postoperative analgesia in cancer surgery].

Clophelinum (0.0014 +/- 0.00007 mg/kg, intravenously) as a component of multicomponent general anesthesia eliminated hemodynamic and endocrine reactions during major abdominal and thoracic surgery in cancer patients, reducing the dosage of calypsol and fentanyl. In the postoperative period clophelinum in combination with Baralgin ensures effective analgesia without the use of any narcotic analgesics.

Adult↗
PubMedDate not supplied

[Butorfanol tartrate (beforol) in cancer surgery].

The results of the clinical study of beforal (butorfanol) ("Spofa", Czechoslovakia), a synthetic analgetic from a class of opiate agonists-antagonists, in 17 cancer patients at all stages of surgical treatment have been summarized. It has been established that beforal is a potent analgetic analogous in antistressor properties to moradol ("Galenika", Yugoslavia), however differing by a more prompt onset and discontinuation of action, thus improving the control over general anesthesia. A comparative assessment of circulation parameters and stress factors (glucose, cortisol, blood plasma STH) has shown that beforal exceeds fentanyl in the efficacy of prevention of surgical trauma during and after extended cancer surgery.

Adult↗